This week’s Expert is Jeff McIntyre, Vice President, Liver Programs at the Global Liver Institute. His major topic is how recent high-level FDA job cuts might affect MASH drug and diagnostics development. He also shares reactions to FibroSIGHT, HistoIndex’s new...
This week’s newsmaker, Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex’s Second Harmonic Generation (SHG) technology and analytics to determine...
Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on what studies on bariatric surgery and drugs in development can tell us about future treatment and explore some clinical...
Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on what studies on bariatric surgery and drugs in development can tell us about future treatment and explore some clinical...
MASLD takes center stage in this week’s episode, exploring how alcohol, diet, and genetics shape disease outcomes and long-term mortality. From Swedish data on cause-specific deaths to personal stories of liver-focused care, the insights hit hard—and help chart a...
SurfingMASH covers two major February conferences: the AASLD Emerging Trends Conference and the Desert Liver Conference, with similar multispecialty perspectives on the entire range of steatotic liver diseases, while Jörn Schattenberg discusses how his practice (and...
